On August 15, 2022 Shanghai’s Bennu Biotherapeutics reported that closed a $15 million Angel+ financing round to support its novel T-cell development programs (Press release, BennuBio, AUG 15, 2022, View Source [SID1234618405]). Founded in 2021, Bennu plans to take cell therapy beyond CAR-T drugs to include T cell types such as TIL, TCR-T and Treg. Although CAR-T has had great success in hematological tumors, it faces several clinical challenges overall. Bennu expects to aim its T cell drugs at solid tumor cancers and autoimmune diseases. The financing was led by INCE Capital with Life Science Park Innovation Fund and Witruth Capital participating.